Erlotinib Terminated Phase 3 Trials for Head and Neck Carcinoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00412217A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer